

# M Hasib Sidiqi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7702637/publications.pdf>

Version: 2024-02-01

68  
papers

700  
citations

567281

15  
h-index

642732

23  
g-index

68  
all docs

68  
docs citations

68  
times ranked

940  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.   | 1.6 | 100       |
| 2  | Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.   | 6.2 | 48        |
| 3  | Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.  | 4.1 | 36        |
| 4  | Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.  | 6.2 | 36        |
| 5  | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.  | 4.1 | 35        |
| 6  | Venetoclax for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 915-920.  | 2.2 | 27        |
| 7  | Daratumumab for the treatment of AL amyloidosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 295-301.   | 1.3 | 27        |
| 8  | Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. <i>Blood Cancer Journal</i> , 2021, 11, 90.   | 6.2 | 27        |
| 9  | Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.   | 5.2 | 23        |
| 10 | Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.   | 5.2 | 23        |
| 11 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.  | 4.1 | 21        |
| 12 | Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.  | 2.0 | 20        |
| 13 | Utility and prognostic value of <sup>18</sup> F- $\beta$ -FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523. | 4.1 | 19        |
| 14 | Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.  | 4.1 | 17        |
| 15 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.  | 6.2 | 16        |
| 16 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.                          | 2.0 | 14        |
| 17 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.  | 4.1 | 14        |
| 18 | The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. <i>Acta Haematologica</i> , 2020, 143, 118-123.  | 1.4 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.   | 4.1 | 14        |
| 20 | Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.                                       | 6.2 | 11        |
| 21 | Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.  | 3.5 | 10        |
| 22 | Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.                                | 4.1 | 10        |
| 23 | Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.                 | 2.0 | 9         |
| 24 | Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.   | 2.4 | 9         |
| 25 | T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica, 2019, 104, e108-e110.   | 3.5 | 9         |
| 26 | Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.   | 2.0 | 8         |
| 27 | Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137. | 2.4 | 8         |
| 28 | The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.   | 6.2 | 8         |
| 29 | Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. American Journal of Hematology, 2021, 96, 446-454. | 4.1 | 8         |
| 30 | Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.                 | 2.4 | 7         |
| 31 | Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.   | 5.2 | 7         |
| 32 | Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.                   | 2.4 | 7         |
| 33 | Immune-mediated neuromuscular complications of graft-versus-host disease. Muscle and Nerve, 2021, 63, 852-860.   | 2.2 | 7         |
| 34 | Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. Blood, 2019, 134, 4106-4106.                  | 1.4 | 6         |
| 35 | Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.   | 6.2 | 6         |
| 36 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.  | 2.4 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises. <i>Cancers</i> , 2022, 14, 113.  | 3.7 | 5         |
| 38 | Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.  | 2.0 | 4         |
| 39 | Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma. <i>Pathology</i> , 2022, 54, 951-953.   | 0.6 | 4         |
| 40 | Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S399-S400. | 2.0 | 3         |
| 41 | A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8055-TPS8055.  | 1.6 | 3         |
| 42 | Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59.   | 6.2 | 3         |
| 43 | Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.  | 1.4 | 2         |
| 44 | Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020, 136, 11-12.   | 1.4 | 2         |
| 45 | Joint Pain and Proteinuria. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1512.   | 7.4 | 1         |
| 46 | Impact of Allogeneic Stem Cell Transplant on Outcomes of Patients with Acute Myeloid Leukemia Based on NPM1 and FLT3 Mutational Status. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S113-S114.  | 2.0 | 1         |
| 47 | Venetoclax For The Treatment of Translocation AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e332.   | 0.4 | 1         |
| 48 | Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.  | 2.4 | 1         |
| 49 | Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.   | 1.4 | 1         |
| 50 | T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. <i>Blood</i> , 2018, 132, 5368-5368.   | 1.4 | 1         |
| 51 | Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , 2018, 60, 174-184.   | 0.8 | 1         |
| 52 | Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.   | 1.4 | 1         |
| 53 | Autologous Stem Cell Transplantation in Patients with AL Amyloidosis with Impaired Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S389-S390.   | 2.0 | 0         |
| 54 | Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1380-1381.  | 3.0 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Autologous Stem Cell Transplant for IgM Related AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S388-S389.  | 2.0 | 0         |
| 56 | Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e301-e302. | 0.4 | 0         |
| 57 | Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8023-8023.   | 1.6 | 0         |
| 58 | Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2018, 132, 3182-3182.   | 1.4 | 0         |
| 59 | Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2147-2147.                      | 1.4 | 0         |
| 60 | Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018, 132, 5610-5610.  | 1.4 | 0         |
| 61 | Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.  | 1.4 | 0         |
| 62 | Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8011-8011.                           | 1.6 | 0         |
| 63 | Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.   | 1.4 | 0         |
| 64 | Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2019, 134, 5556-5556.  | 1.4 | 0         |
| 65 | Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8516-8516.  | 1.6 | 0         |
| 66 | Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.  | 1.0 | 0         |
| 67 | Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients. <i>Blood</i> , 2020, 136, 44-45.  | 1.4 | 0         |
| 68 | Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 23-23.                                 | 1.4 | 0         |